Mitech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Mitech makes non-vascular stents, small mesh tubes inserted into digestive-tract passages such as the esophagus or colon to keep them open, and supplies them to hospitals and clinicians in South Korea and overseas.
The company, listed on KOSDAQ (South Korea's tech and small-cap exchange), also distributes gastrointestinal endoscopy equipment domestically. Its core stent business spans both malignant and benign conditions, as well as veterinary use, and the company holds the updated European medical-device regulatory certification (CE MDR) that is required to access EU and CE-aligned markets.
Summary is AI-generated and may contain errors · figures from DART filings
Mitech claims to have been the first in South Korea to develop a non-vascular stent, and it conducts new product development in collaboration with major domestic hospitals and government-funded research programs.
Mitech in five facts
What does Mitech do?
Mitech makes non-vascular stents, small mesh tubes inserted into digestive-tract passages such as the esophagus or colon to keep them open, and supplies them to hospitals and clinicians in South Korea and overseas.
Where is Mitech listed and in which sector?
Mitech (Korean name: 엠아이텍) trades under KRX code 179290 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Mitech?
Its market capitalisation was US$111.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Mitech's latest annual revenue and operating profit?
For fiscal year 2025, Mitech reported revenue of US$50.7M, operating profit of US$15.6M and net income of US$0, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 24.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Decision to acquire shares/equity in another company (voluntary)
Mitech updated the disclosed terms of an acquisition of PrediSurge SAS, now worth US$7.37M.
M&A · Sep 28 - Decision to acquire shares/equity in another company (voluntary)
Mitech disclosed an acquisition of PrediSurge SAS, worth US$6.84M.
M&A · Jul 27 - [Amended] Cash/in-kind dividend decision
Mitech updated its declared cash dividend of US$0.08 per share, equal to about 1.8% of the recent share price.
Dividend · Apr 21 - Cash/in-kind dividend decision
Mitech declared a cash dividend of US$0.08 per share.
Dividend · Feb 25 - Change of less than 30% in revenue or profit/loss structure (15% for large companies) (voluntary)
Mitech reported consolidated results for FY2025: revenue of US$46.6M (+24.9% year on year), operating profit of US$14.4M (+17.6% year on year) and net income of US$14.1M (+11.2% year on year).
Earnings · Feb 25